ENGLISH
|
JAPANESE
|
CONNECT WITH US:
Home
About
Contact
Log in
*
Home
Press release
Apr 02, 2020 16:30 JST
Source:
Agilex Biolabs
Agilex Biolabs Taps Biopharma Leader Dr Caroline Popper for Board Chair as part of APAC Bioanalytical Services Growth
ADELAIDE, AUS, Apr 02, 2020 - (ACN Newswire) - Award-winning Australian bioanalytical laboratory Agilex Biolabs announced today it has appointed US-based Dr Caroline Popper, MBBS, MPH as Board Chair as part of its APAC clinical trials bioanalytics growth plans.
Dr Caroline Popper
More than 38% of Agilex Biolabs' biotech clients already come from the APAC region - primarily from China and South Korea. APAC clients are particularly attracted by Agilex' FDA-inspected status, and the more than 40% rebate on clinical trial spend that applies in Australia.
Agilex Biolabs specializes in bioanalysis of small molecules and biologics for PK, immunogenicity, biomarkers and immunological pharmacodynamics assessments, and the only FDA-inspected lab of its type in the region, is located in Adelaide, South Australia in a science and biotech specialist hub.
Dr Popper was first appointed to the Agilex Biolabs Board in July 2019.
Agilex Biolabs CEO Jason Valentine said:
"We are extremely pleased Dr Popper accepted the Board Chair role and we look forward to an exciting phase of growth under her guidance."
"Dr Caroline Popper is a medical doctor, pathologist, health economist, medical consultant and experienced company director, with over 20 years of hands on experience in the healthcare, medical devices and drug discovery fields.
She has managed a wide range of diagnostics, device and drug discovery businesses in both Fortune 500 and start-up settings, at amongst others, Becton Dickinson, bioMerieux, and MDS."
Dr Popper said:
"My clinical experience enables me to help interpret relevant market forces, develop strategies and create partnerships that thrive in the global and fast changing and challenging health care landscape."
"Agilex Biolabs is a stand-out leader in the pharma services space and I look forward to taking on this significant role and being part of the next phase of growth for the company, leveraging its position in the important APAC region."
"The Aglilex Biolabs team of scientists and specialist PhDs is quite exceptional making it well positioned to rapidly deliver bioanalytics for biopharma clients running clinical trials in Australia, Asia and the US, and the EU."
The company specialises in bioanalysis of small molecules and biologics for PK, immunogenicity, biomarkers and immunological pharmacodynamics assessments utilising LC-MS/MS, immunoassay (Mesoscale, Gurolab, Luminex) and flow cytometry (BD FACSymphony A3, 20 colour cell analyser).
Agilex also offers pharmacodynamics services that include immunobiology services using the latest state-of-the-art technology to support immunology, cell biology and mode of action assays, including:
- Immunophenotyping
- Receptor occupancy
- Cytokine release assays (whole blood or PBMC stimulation assays) and cytokine/biomarker profiling
- PBMC assays and cellular mechanism of action assays (eg: ADCC)
CEO Jason Valentine said:
"Our FDA-inspected facilities have more than 65 dedicated laboratory staff, and annually support more than 80 clinical trials. This year we will analyse more than 60,000 samples for pharma/biotechs from US, Europe and APAC."
"By combining specialised expertise, technological innovation and a 20-year track record, we have supported hundreds of preclinical and clinical trials around the world."
"Our world-class bioanalytical facilities have OECD GLP Recognition with NATA (Australian Government OECD GLP Compliance monitoring authority) and ISO 17025 Accreditation for global recognition."
Learn more about Agilex Biolabs in this Video:
https://youtu.be/3lyodiqqM_k
About Agilex Biolabs
Agilex Biolabs began as a group of academic scientists providing clinical trial and bioanalytical services to the local Australian pharmaceutical industry in the 1980's, and has now grown into a global business for early phase clinical trials. In our 20 years of performing regulated bioanalysis of small and large molecules, we have accelerated hundreds of preclinical and clinical trials around the world. Today, our clients include many of the leading pharmaceutical and biotechnology companies in Asia, Europe and the USA. Call +61 8 83028777 or +1 800 247 1909 or visit
https://www.agilexbiolabs.com/
.
Agilex Biolabs is built upon four core values that drive our performance:
- Scientific excellence and technological innovation
- Customer focus
- Data integrity and quality assurance
- Timeliness/speed
See us featured in Endpoints
https://tinyurl.com/uqmkzcu
Media Contact:
Team@DMGPR.Com
David James
AU: +61 2 8218 2144
USA: +1 415 951 3228
Asia: +65 3159 3427
Source: Agilex Biolabs
Sectors: BioTech, Healthcare & Pharm
Copyright ©2026 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
Latest Release
Eisai Deepens Body of Clinical Evidence for LENVIMA(R) (Lenvatinib) Across Established Indications at ASCO 2026
May 22, 2026 00:23 JST
Honda to Begin Sales of Super-ONE Compact EV
May 22, 2026 00:16 JST
Fujitsu supports the Panasonic Group in accelerating its sustainability management through the implementation of a CFP calculation solution
May 21, 2026 13:57 JST
Sharp Launches Poketomo Conversational AI Character in Taiwan
May 21, 2026 13:55 JST
Hitachi Energy's HMAX Energy service solutions strengthen long-term reliability for Akaysha Energy's Ulinda Park BESS
May 21, 2026 13:40 JST
Heads of State/Government, Ministers, and Senior Officials from 30 Countries to Convene in Tokyo for the Island States Ocean Summit
May 20, 2026 17:00 JST
Trusco Nakayama and Fujitsu accelerate personnel transfer decision-making process with data and AI
May 20, 2026 13:50 JST
Hitachi announces strategic partnership with Anthropic to strengthen "Lumada 3.0" through frontier AI
May 19, 2026 23:09 JST
SMBC Group, Fujitsu and SoftBank agree on alliance to build Japan-made platform for sustainable healthcare
May 19, 2026 13:37 JST
Ashikaga Bank launches Fujitsu's service supporting digitalization of Inheritance Procedure
May 18, 2026 18:13 JST
Sharp to Exhibit at The 3rd SPEXA - Space Business Expo
May 18, 2026 17:34 JST
MHIEC Receives Waste Treatment Technology Verification Report from JESC for Its Fluidized Bed-type Gasification and Reforming System
May 18, 2026 17:17 JST
MHI Thermal Systems Receives A' Design Awards
-- Recognition at Italy's International Design Competition for the Hydrolution EZY Series of Air-to-Water Heat Pumps and the ZT Series of Residential-Use Air-Conditioners --
May 18, 2026 16:26 JST
Tallgrass and Mitsubishi Power Americas Announce Turbine Allocation for Cheyenne Power Hub
May 18, 2026 15:15 JST
JCB and Wonder Advance Cashless Taxi Payments in Hong Kong
May 18, 2026 10:00 JST
NEC completes construction of approximately 2,250 km EMCS submarine cable linking Pacific island nations
May 15, 2026 17:36 JST
Fujitsu and Science Tokyo launch joint research hub for quantum hardware advancement and talent development
May 15, 2026 17:12 JST
Fujitsu and IBM Japan formalize collaboration in healthcare sector
May 15, 2026 16:42 JST
Toyota Launches All-New Land Cruiser "FJ" Series in Japan
May 15, 2026 15:24 JST
Mitsubishi Motors Signs Memorandum of Understanding with FPT Japan Holdings to Study Collaboration in Software and Digital Domain
May 15, 2026 15:10 JST
More Latest Release >>
Related Release
Elevating Australia's Scientific Acumen: Large Molecule Facility Doubles Size of Australia's Top Bioanalytical Laboratory
May 12 2022 15:00 JST
Agilex Biolabs Shares How to Select the Right Bioanalytical Tools for Immuno-oncology and Vaccines Studies - OCT Webinar
October 19 2021 15:00 JST
Agilex Biolabs Announced as Citeline Award Finalist for COVID-19 Vaccine Toxicology Preclinical Research
September 24 2021 09:00 JST
Agilex Biolabs Partners with Endpoints News for the First Webinar on Rapid Vaccine Development in Australia
August 26 2021 13:00 JST
Premier of South Australia Launches $1.5m Vaccine and Immunobiology State-of-the art Laboratory for APAC Clinical Trials
July 14 2021 17:00 JST
Agilex Biolabs and Gyros Protein Technologies Partner for BioAnalysis Zone Webinar on Singlicate Analysis
May 31 2021 13:00 JST
Agilex Biolabs Partners with Endpoints News on Deconvoluting Inflammation and Immunology for Clinical Trials
May 21 2021 11:00 JST
Agilex Biolabs' Toxicology Tapped for SARS-CoV-2 Vaccine Research
May 17 2021 21:00 JST
Agilex Biolabs Congratulates Bionomics Limited on BNC210 PK Results
April 30 2021 13:00 JST
Agilex Biolabs and B2S Life Sciences on Immunoassay Bioanalysis for Clinical Trials
April 29 2021 04:00 JST
More Press release >>